Cyanotech Corp stock (US2324373016): Recent reverse split and ticker change

Cyanotech Corp, a producer of microalgae-based nutritional products, recently executed a complex stock split restructuring. The company performed a 1-for-400 reverse stock split, immediately followed by a 400-for-1 forward stock split, resulting in a net 1-for-1 adjustment but with a ticker symbol change to CYAND. This corporate action was tracked by Robinhood as of recent updates.

The restructuring aims to meet certain marketplace requirements or optimize share structure, though specific rationale was not detailed in available disclosures. Investors trading CYAN shares should note the transition to the new CYAND ticker on applicable platforms. Such actions are common for OTC-listed companies adjusting compliance or liquidity profiles.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

Cyanotech Corp: core business model

Cyanotech Corp specializes in the cultivation and production of microalgae-based ingredients for human nutrition and animal health. The company operates a facility in Hawaii, focusing on high-value products like astaxanthin, a potent antioxidant derived from Haematococcus pluvialis algae, and spirulina, a nutrient-dense blue-green algae. These products are sold under brands such as BioAstin and Hawaiian Spirulina to supplement manufacturers worldwide.

The business model revolves around sustainable aquaculture in controlled environments to ensure purity and potency. Cyanotech emphasizes natural, non-GMO production methods, targeting the growing demand for clean-label superfoods in the US health supplement market, which appeals to retail investors interested in biotech-agriculture crossovers.

Main revenue and product drivers for Cyanotech Corp

Astaxanthin remains the primary revenue driver, used in supplements for joint health, skin care, and eye support. Spirulina contributes through immune-boosting and protein-rich formulations. Sales are primarily B2B to formulators, with distribution via major US retailers and online channels, providing exposure to the expanding $50+ billion US dietary supplement sector.

Recent corporate actions like the stock split do not alter operational fundamentals but may signal efforts to enhance trading visibility on OTC markets. According to company disclosures on its investor site as of prior filings, revenue is driven by volume growth in premium algae extracts amid rising consumer interest in natural antioxidants.

Industry trends and competitive position

The microalgae ingredients market is expanding with US demand for plant-based superfoods, projected to grow at double-digit rates through 2030 per sector reports. Cyanotech holds a niche leadership in astaxanthin production, benefiting from Hawaii's ideal climate and proprietary strains, differentiating it from synthetic competitors.

For US investors, the company's focus on evidence-backed nutraceuticals aligns with trends in preventive health, though it faces competition from larger players like DSM and BASF in broader carotenoids.

Conclusion

Cyanotech Corp's recent reverse-forward stock split and ticker change to CYAND reflect ongoing efforts to adapt its market presence on OTC platforms. The core microalgae business continues to target growth in the US nutraceuticals space, with astaxanthin and spirulina as key pillars. Investors monitoring small-cap biotech names may track upcoming filings for operational updates.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.